Can-Fite BioPharma Ltd. Financials

CANF

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE December

Financial Health Signals

Financial Profile 38/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Can-Fite BioPharma Ltd. has an operating margin of -1206.2%, meaning the company retains $-1206 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -1103.0% the prior year.

Growth

Can-Fite BioPharma Ltd.'s revenue declined 9.3% year-over-year, from $743K to $674K. This contraction results in a growth score of 2/100.

Leverage

Can-Fite BioPharma Ltd. carries a low D/E ratio of 0.68, meaning only $0.68 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 86/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 4.38, Can-Fite BioPharma Ltd. holds $4.38 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Can-Fite BioPharma Ltd. generated -$7.6M in operating cash flow, capex of $5K consumed most of it, leaving -$7.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

1/9

Can-Fite BioPharma Ltd. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.97x

For every $1 of reported earnings, Can-Fite BioPharma Ltd. generates $0.97 in operating cash flow (-$7.6M OCF vs -$7.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-27.9x

Can-Fite BioPharma Ltd. earns $-27.9 in operating income for every $1 of interest expense (-$8.1M vs $291K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

This page shows Can-Fite BioPharma Ltd. (CANF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

$674K

YoY-9.3%

5Y CAGR-19.8%

Can-Fite BioPharma Ltd. generated $674K in revenue in fiscal year 2024. This represents a decrease of 9.3% from the prior year.

EBITDA

-$8.1M

YoY+0.7%

Can-Fite BioPharma Ltd.'s EBITDA was -$8.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.7% from the prior year.

Free Cash Flow

-$7.6M

YoY+9.5%

Can-Fite BioPharma Ltd. generated -$7.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 9.5% from the prior year.

Net Income

-$7.9M

YoY-3.2%

Can-Fite BioPharma Ltd. reported -$7.9M in net income in fiscal year 2024. This represents a decrease of 3.2% from the prior year.

EPS (Diluted)

$0.00

YoY+100.0%

Can-Fite BioPharma Ltd. earned $0.00 per diluted share (EPS) in fiscal year 2024. This represents an increase of 100.0% from the prior year.

Cash & Debt

$4.8M

YoY+12.8%

5Y CAGR+12.3%

Can-Fite BioPharma Ltd. held $4.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

2.98B

YoY+119.4%

Can-Fite BioPharma Ltd. had 2.98B shares outstanding in fiscal year 2024. This represents an increase of 119.4% from the prior year.

Gross Margin

N/A

Operating Margin

-1206.2%

YoY-103.3pp

5Y CAGR-615.3pp

Can-Fite BioPharma Ltd.'s operating margin was -1206.2% in fiscal year 2024, reflecting core business profitability. This is down 103.3 percentage points from the prior year.

Net Margin

-1169.1%

YoY-141.7pp

5Y CAGR-547.8pp

Can-Fite BioPharma Ltd.'s net profit margin was -1169.1% in fiscal year 2024, showing the share of revenue converted to profit. This is down 141.7 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$5.8M

YoY-3.8%

5Y CAGR-12.1%

Can-Fite BioPharma Ltd. invested $5.8M in research and development in fiscal year 2024. This represents a decrease of 3.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5K

YoY+150.0%

5Y CAGR+10.8%

Can-Fite BioPharma Ltd. invested $5K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 150.0% from the prior year.

CANF Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$674K-9.3%	$743K-8.3%	$810K-5.0%	$853K+11.8%	$763K-62.5%	$2.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.8M-3.8%	$6.0M-22.9%	$7.8M-21.2%	$9.8M-17.6%	$12.0M+8.9%	$11.0M
SG&A Expenses	$3.0M+3.1%	$3.0M+1023.6%	$263K-43.6%	$466K+47.0%	$317K-89.7%	$3.1M
Operating Income	-$8.1M+0.8%	-$8.2M+18.8%	-$10.1M+21.4%	-$12.8M+9.2%	-$14.1M-17.8%	-$12.0M
Interest Expense	-$291K+42.5%	-$506K-127.9%	-$222K-197.8%	$227K+174.7%	-$304K+50.8%	-$618K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$7.9M-3.2%	-$7.6M+25.0%	-$10.2M+19.4%	-$12.6M+12.7%	-$14.4M-14.4%	-$12.6M
EPS (Diluted)	$0.00+100.0%	$-0.010.0%	$-0.01+66.7%	$-0.03+25.0%	$-0.04	N/A

Metric	Q2'25	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21	Q2'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CANF Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$9.1M-8.7%	$10.0M+7.6%	$9.3M-54.2%	$20.3M+112.7%	$9.5M+16.5%	$8.2M
Current Assets	$9.0M-9.3%	$9.9M+8.2%	$9.2M-54.4%	$20.1M+113.5%	$9.4M+31.6%	$7.1M
Cash & Equivalents	$4.8M+12.8%	$4.3M+43.7%	$3.0M-32.2%	$4.4M-46.9%	$8.3M+206.6%	$2.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	$0	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.7M-1.7%	$3.7M-22.1%	$4.8M-18.1%	$5.9M+70.2%	$3.4M-39.8%	$5.7M
Current Liabilities	$2.1M+1.6%	$2.0M-19.3%	$2.5M-8.4%	$2.7M+115.1%	$1.3M-61.2%	$3.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$5.4M-12.9%	$6.2M+39.6%	$4.5M-68.9%	$14.4M+136.8%	$6.1M+148.7%	$2.4M
Retained Earnings	-$166.4M-5.0%	-$158.5M-5.1%	-$150.8M-7.2%	-$140.7M-12.1%	-$125.5M-13.7%	-$110.3M

Metric	Q2'25	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21	Q2'21
Total Assets	$7.7M-15.4%	$9.1M-8.7%	$10.0M-9.5%	$11.0M+18.8%	$9.3M-37.0%	$14.7M-27.2%	$20.3M+109.2%	$9.7M
Current Assets	$7.6M-15.1%	$9.0M-9.3%	$9.9M-9.2%	$10.9M+19.1%	$9.2M-37.2%	$14.6M-27.3%	$20.1M+110.1%	$9.6M
Cash & Equivalents	$6.5M+33.8%	$4.8M+12.8%	$4.3M+23.7%	$3.5M+16.1%	$3.0M+73.9%	$1.7M-61.0%	$4.4M-41.8%	$7.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$0	$0	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.5M-4.0%	$3.7M-1.7%	$3.7M-9.9%	$4.2M-13.6%	$4.8M-0.9%	$4.9M-17.3%	$5.9M+2.6%	$5.7M
Current Liabilities	$2.1M+3.3%	$2.1M+1.6%	$2.0M-9.5%	$2.2M-10.8%	$2.5M+16.2%	$2.2M-21.1%	$2.7M+15.7%	$2.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.2M-23.0%	$5.4M-12.9%	$6.2M-9.2%	$6.9M+53.7%	$4.5M-54.8%	$9.9M-31.2%	$14.4M+263.6%	$4.0M
Retained Earnings	-$171.2M-2.9%	-$166.4M-5.0%	-$158.5M-2.2%	-$155.1M-2.8%	-$150.8M-3.8%	-$145.3M-3.3%	-$140.7M-7.7%	-$130.6M

CANF Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$7.6M+9.5%	-$8.4M+21.9%	-$10.8M-9.6%	-$9.9M+18.3%	-$12.1M-8.8%	-$11.1M
Capital Expenditures	$5K+150.0%	$2K-77.8%	$9K-18.2%	$11K-57.7%	$26K+766.7%	$3K
Free Cash Flow	-$7.6M+9.5%	-$8.4M+21.9%	-$10.8M-9.5%	-$9.9M+18.4%	-$12.1M-9.0%	-$11.1M
Investing Cash Flow	$1.5M+200.2%	$498K-94.8%	$9.5M+165.5%	-$14.5M-55711.5%	-$26K-766.7%	-$3K
Financing Cash Flow	$6.7M-26.6%	$9.1M	N/A	$20.5M+15.7%	$17.7M+73.9%	$10.2M
Dividends Paid	N/A	N/A	N/A	$2.6M+262.2%	$715K	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21	Q2'21
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CANF Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1206.2%-103.3pp	-1103.0%+143.5pp	-1246.4%+259.1pp	-1505.5%+347.6pp	-1853.1%-1262.2pp	-590.9%
Net Margin	-1169.1%-141.7pp	-1027.5%+228.5pp	-1255.9%+223.0pp	-1478.9%+414.0pp	-1892.9%-1271.6pp	-621.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-86.4%-10.0pp	-76.4%+33.2pp	-109.6%-47.3pp	-62.3%+89.4pp	-151.7%+2.8pp	-154.4%
Current Ratio	4.38-0.5	4.91+1.2	3.66-3.7	7.35-0.1	7.41+5.2	2.18
Debt-to-Equity	0.68+0.1	0.60-0.5	1.08+0.7	0.41-0.2	0.57-1.8	2.35
FCF Margin	-1133.8%+2.4pp	-1136.2%+198.4pp	-1334.6%-177.6pp	-1157.0%+427.4pp	-1584.4%-1038.8pp	-545.6%

Metric	Q2'25	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21	Q2'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	3.60-0.8	4.38-0.5	4.91+0.0	4.89+1.2	3.66-3.1	6.78-0.6	7.35+3.3	4.05
Debt-to-Equity	0.85+0.2	0.68+0.1	0.600.0	0.60-0.5	1.08+0.6	0.49+0.1	0.41-1.0	1.45
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

$5.4M

$45.9M

$15.2M

$9.6M

Adaptimmune Therapeutics Plc ADAP

$14.6M

Frequently Asked Questions

What is Can-Fite BioPharma Ltd.'s annual revenue?

Can-Fite BioPharma Ltd. (CANF) reported $674K in total revenue for fiscal year 2024. This represents a -9.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Can-Fite BioPharma Ltd.'s revenue growing?

Can-Fite BioPharma Ltd. (CANF) revenue declined by 9.3% year-over-year, from $743K to $674K in fiscal year 2024.

Is Can-Fite BioPharma Ltd. profitable?

No, Can-Fite BioPharma Ltd. (CANF) reported a net income of -$7.9M in fiscal year 2024, with a net profit margin of -1169.1%.

What is Can-Fite BioPharma Ltd.'s earnings per share (EPS)?

Can-Fite BioPharma Ltd. (CANF) reported diluted earnings per share of $0.00 for fiscal year 2024. This represents a 100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Can-Fite BioPharma Ltd.'s EBITDA?

Can-Fite BioPharma Ltd. (CANF) had EBITDA of -$8.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Can-Fite BioPharma Ltd.'s operating margin?

Can-Fite BioPharma Ltd. (CANF) had an operating margin of -1206.2% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Can-Fite BioPharma Ltd.'s net profit margin?

Can-Fite BioPharma Ltd. (CANF) had a net profit margin of -1169.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Can-Fite BioPharma Ltd.'s free cash flow?

Can-Fite BioPharma Ltd. (CANF) generated -$7.6M in free cash flow during fiscal year 2024. This represents a 9.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Can-Fite BioPharma Ltd.'s operating cash flow?

Can-Fite BioPharma Ltd. (CANF) generated -$7.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Can-Fite BioPharma Ltd.'s total assets?

Can-Fite BioPharma Ltd. (CANF) had $9.1M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Can-Fite BioPharma Ltd.'s capital expenditures?

Can-Fite BioPharma Ltd. (CANF) invested $5K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Can-Fite BioPharma Ltd. spend on research and development?

Can-Fite BioPharma Ltd. (CANF) invested $5.8M in research and development during fiscal year 2024.

How many shares does Can-Fite BioPharma Ltd. have outstanding?

Can-Fite BioPharma Ltd. (CANF) had 2.98B shares outstanding as of fiscal year 2024.

What is Can-Fite BioPharma Ltd.'s current ratio?

Can-Fite BioPharma Ltd. (CANF) had a current ratio of 4.38 as of fiscal year 2024, which is generally considered healthy.

What is Can-Fite BioPharma Ltd.'s debt-to-equity ratio?

Can-Fite BioPharma Ltd. (CANF) had a debt-to-equity ratio of 0.68 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Can-Fite BioPharma Ltd.'s return on assets (ROA)?

Can-Fite BioPharma Ltd. (CANF) had a return on assets of -86.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Can-Fite BioPharma Ltd.'s cash runway?

Based on fiscal year 2024 data, Can-Fite BioPharma Ltd. (CANF) had $4.8M in cash against an annual operating cash burn of $7.6M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Can-Fite BioPharma Ltd.'s Piotroski F-Score?

Can-Fite BioPharma Ltd. (CANF) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Can-Fite BioPharma Ltd.'s earnings high quality?

Can-Fite BioPharma Ltd. (CANF) has an earnings quality ratio of 0.97x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Can-Fite BioPharma Ltd. cover its interest payments?

Can-Fite BioPharma Ltd. (CANF) has an interest coverage ratio of -27.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Can-Fite BioPharma Ltd.?

Can-Fite BioPharma Ltd. (CANF) scores 38 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.